Compare Lattice Semiconductor Corporation Common Stock (LSCC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lattice Semiconductor Corporation Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Lattice Semiconductor Corporation Common Stock trades at $111.07 (market cap $17.90B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Lattice Semiconductor Corporation Common Stock is far larger — about 18.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is more actively traded (4,325,710 versus 1,042,232). Which is the better fit depends on your goals — on Pluang, investors hold Lattice Semiconductor Corporation Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LSCC | MRVI | |
|---|---|---|
Market Cap | $17.90B | $972.90M |
Volume | 1,042,232 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $155.27 | $9.00 |
52-Week Low | $61.73 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $17.77B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lattice Semiconductor (LSCC) trades at $121.15, down 1.38% today, with a bullish technical signal from moving averages. The company shows strong revenue growth projections from $523M in 2025 to $651M in 2026, though current valuation metrics remain elevated with a P/E of 504.2. Recent news highlights leadership in AI infrastructure security and new FPGA product launches, supported by overwhelmingly positive analyst sentiment with 88% buy ratings.
LSCC presents growth potential through AI-driven semiconductor demand and expanding product portfolio, but faces risks from high valuations and competitive pressures. The consensus price target of $162.14 suggests 34% upside, though investors should monitor execution on projected margin expansion from 0.58% to 5.57% net profit margin.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Lattice Semiconductor Corporation Common Stock
Lattice Semiconductor develops low-power programmable chips, known as FPGAs. Its products are used in communications, computing, industrial, and automotive applications.
Read more on LSCC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
